Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  • Interventional
  • Recruiting
  • NCT03013998

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.